Hvis vi ikke var i Danmark - Dansk Myelomatose Forening<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/\" \/>\n<meta property=\"og:locale\" content=\"da_DK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hvis vi ikke var i Danmark\" \/>\n<meta property=\"og:description\" content=\"De nyeste og livreddende behandlinger gives dagligt i andre lande Når en sygdom som knoglemarvskræft, myelomatose, er uhelbredelig, bliver det afgørende, at de nye livreddende behandlinger, som fx CAR-T celleterapi og de bispecifikke behandlinger, er tilgængelige. Her falder Danmark nu helt bagud og bliver et behandlingsmæssigt u-land, eller som Kristian Lund skriver i Sundhedstinget: Terra ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/\" \/>\n<meta property=\"og:site_name\" content=\"Dansk Myelomatose Forening\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-19T07:15:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-1024x683.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Estimeret l\u00e6setid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/\",\"url\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/\",\"name\":\"Hvis vi ikke var i Danmark - Dansk Myelomatose Forening\",\"isPartOf\":{\"@id\":\"https:\/\/www.myelomatose.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-1024x683.jpg\",\"datePublished\":\"2023-10-18T17:08:12+00:00\",\"dateModified\":\"2023-11-19T07:15:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#breadcrumb\"},\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#primaryimage\",\"url\":\"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-scaled.jpg\",\"contentUrl\":\"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"N\u00e5r de livreddende behandlinger ikke godkendes af Meddicinr\u00e5det efterlades patienten uden h\u00e5b.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\/\/www.myelomatose.dk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Giv os tid\",\"item\":\"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Hvis vi ikke var i Danmark\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.myelomatose.dk\/#website\",\"url\":\"https:\/\/www.myelomatose.dk\/\",\"name\":\"Dansk Myelomatose Forening\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.myelomatose.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.myelomatose.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"da-DK\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.myelomatose.dk\/#organization\",\"name\":\"Dansk Myelomatose Forening\",\"url\":\"https:\/\/www.myelomatose.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/www.myelomatose.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.myelomatose.dk\/content\/uploads\/2024\/10\/myelomatose-logo.png\",\"contentUrl\":\"https:\/\/www.myelomatose.dk\/content\/uploads\/2024\/10\/myelomatose-logo.png\",\"width\":1280,\"height\":321,\"caption\":\"Dansk Myelomatose Forening\"},\"image\":{\"@id\":\"https:\/\/www.myelomatose.dk\/#\/schema\/logo\/image\/\"}}]}<\/script>\n","yoast_head_json":{"title":"Hvis vi ikke var i Danmark - Dansk Myelomatose Forening","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/","og_locale":"da_DK","og_type":"article","og_title":"Hvis vi ikke var i Danmark","og_description":"De nyeste og livreddende behandlinger gives dagligt i andre lande Når en sygdom som knoglemarvskræft, myelomatose, er uhelbredelig, bliver det afgørende, at de nye livreddende behandlinger, som fx CAR-T celleterapi og de bispecifikke behandlinger, er tilgængelige. Her falder Danmark nu helt bagud og bliver et behandlingsmæssigt u-land, eller som Kristian Lund skriver i Sundhedstinget: Terra ... Read more","og_url":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/","og_site_name":"Dansk Myelomatose Forening","article_modified_time":"2023-11-19T07:15:55+00:00","og_image":[{"url":"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-1024x683.jpg"}],"twitter_misc":{"Estimeret l\u00e6setid":"2 minutter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/","url":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/","name":"Hvis vi ikke var i Danmark - Dansk Myelomatose Forening","isPartOf":{"@id":"https:\/\/www.myelomatose.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#primaryimage"},"image":{"@id":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#primaryimage"},"thumbnailUrl":"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-1024x683.jpg","datePublished":"2023-10-18T17:08:12+00:00","dateModified":"2023-11-19T07:15:55+00:00","breadcrumb":{"@id":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#breadcrumb"},"inLanguage":"da-DK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/"]}]},{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#primaryimage","url":"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-scaled.jpg","contentUrl":"https:\/\/www.myelomatose.dk\/content\/uploads\/2023\/10\/istock-508516583-scaled.jpg","width":2560,"height":1707,"caption":"N\u00e5r de livreddende behandlinger ikke godkendes af Meddicinr\u00e5det efterlades patienten uden h\u00e5b."},{"@type":"BreadcrumbList","@id":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/hvis-det-ikke-var-i-danmark\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/www.myelomatose.dk\/"},{"@type":"ListItem","position":2,"name":"Giv os tid","item":"https:\/\/www.myelomatose.dk\/patienter-med-knoglemarvskraeft-myelomatose-giv-os-tid\/"},{"@type":"ListItem","position":3,"name":"Hvis vi ikke var i Danmark"}]},{"@type":"WebSite","@id":"https:\/\/www.myelomatose.dk\/#website","url":"https:\/\/www.myelomatose.dk\/","name":"Dansk Myelomatose Forening","description":"","publisher":{"@id":"https:\/\/www.myelomatose.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.myelomatose.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"da-DK"},{"@type":"Organization","@id":"https:\/\/www.myelomatose.dk\/#organization","name":"Dansk Myelomatose Forening","url":"https:\/\/www.myelomatose.dk\/","logo":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/www.myelomatose.dk\/#\/schema\/logo\/image\/","url":"https:\/\/www.myelomatose.dk\/content\/uploads\/2024\/10\/myelomatose-logo.png","contentUrl":"https:\/\/www.myelomatose.dk\/content\/uploads\/2024\/10\/myelomatose-logo.png","width":1280,"height":321,"caption":"Dansk Myelomatose Forening"},"image":{"@id":"https:\/\/www.myelomatose.dk\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/pages\/10102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/users\/10487"}],"replies":[{"embeddable":true,"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/comments?post=10102"}],"version-history":[{"count":106,"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/pages\/10102\/revisions"}],"predecessor-version":[{"id":11694,"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/pages\/10102\/revisions\/11694"}],"up":[{"embeddable":true,"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/pages\/9918"}],"wp:attachment":[{"href":"https:\/\/www.myelomatose.dk\/wp-json\/wp\/v2\/media?parent=10102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Når en sygdom som knoglemarvskræft, myelomatose, er uhelbredelig, bliver det afgørende, at de nye livreddende behandlinger, som fx CAR-T celleterapi og de bispecifikke behandlinger, er tilgængelige.<\/p>